Novo Nordisk’s GLP-1 agonist Ozempic has shown efficacy in yet another indication, achieving a 24% reduction in kidney disease-related events in people with type 2 diabetes and chronic kidney disease ...
A technical build log of the Multi-Agent Control Room, where AI agents pay invoices, escalate denials, and every action is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results